While Summit Therapeutics Inc has underperformed by -7.54%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SMMT rose by 322.30%, with highs and lows ranging from $33.89 to $2.10, whereas the simple moving average jumped by 20.98% in the last 200 days.
On February 28, 2025, Goldman started tracking Summit Therapeutics Inc (NASDAQ: SMMT) recommending Buy. A report published by Truist on January 08, 2025, Initiated its previous ‘Buy’ rating for SMMT. Wells Fargo also rated SMMT shares as ‘Overweight’, setting a target price of $30 on the company’s shares in an initiating report dated December 11, 2024. Jefferies Initiated an Buy rating on December 06, 2024, and assigned a price target of $31. JMP Securities initiated its ‘Mkt Outperform’ rating for SMMT, as published in its report on November 04, 2024. Citigroup’s report from September 27, 2024 suggests a price prediction of $23 for SMMT shares, giving the stock a ‘Neutral’ rating. H.C. Wainwright also rated the stock as ‘Buy’.
Analysis of Summit Therapeutics Inc (SMMT)
In order to gain a clear picture of Summit Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -94.89% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 10.15, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 2.38M can be a very valuable indicator of volatility for SMMT stock. On a monthly basis, the volatility of the stock is set at 8.66%, whereas on a weekly basis, it is put at 9.70%, with a gain of 1.54% over the past seven days. Furthermore, long-term investors anticipate a median target price of $36.29, showing growth from the present price of $19.13, which can serve as yet another indication of whether SMMT is worth investing in or should be passed over.
How Do You Analyze Summit Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 84.42%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 12.62% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
SMMT shares are owned by institutional investors to the tune of 12.62% at present.
